Pfizer’s shares sank significantly on Tuesday as global markets rose steadily. Analysts downgraded the firm over no clear growth drivers. Some investors worry the pipeline lacks depth and leadership remains unsettled.
But Pfizer earned a key approval: the first CDK4/6 maintenance therapy for advanced HER2-positive breast cancer. However, the stock losses eclipsed the good news. Offices in Midtown Manhattan cleared out after beams cracked, raising collapse concerns.